Delineating IL-2

While Celgene Corp. has a history of entering creative deals that enable its smaller partners to retain control over early development, Delinia Inc.’s clinically validated approach to treating autoimmune diseases, paired with preclinical proof-of-concept data, made the start-up ripe for a straightforward takeout.

It didn’t hurt that the biotech received multiple bids...